Printer Friendly

Long oxygen desaturation time is a risk factor for metabolic syndrome/Uzun oksijen desaturasyon suresi metabolik sendrom icin risk faktorudur.


Obstructive sleep apnea syndrome (OSAS) is a medical condition characterized by complete or partial obstruction of the upper respiratory airways occurring during sleep (1). The incidence is approximately 4% in adult males and 2% in adult females (2). OSAS is associated with complex hemodynamic changes that are related to systemic hypertension (3), pulmonary hypertension (4), hypercoagulability (5,6), endothelial dysfunction (7), inflammation (8), coronary artery disease (9), insulin resistance (10), and dyslipidemia (9,11). Thus, OSAS can contribute to the development of cardiac and vascular problems. OSAS and metabolic syndrome (MS) share some common features. MS is also a heterogeneous disorder that is associated with insulin resistance (12), diabetes mellitus (13), hypertension (14), dyslipidemia (15), obesity (16), coronary artery disease (17), endothelial dysfunction (18), and hypercoagulability (19). All of these components of MS are known to increase cardiovascular mortality. In Turkey, the prevalence of MS in adults ([greater than or equal to] 20 years of age) was defined as 35% by METSAR and 37.1% by TEKHARF (20,21) studies.

OSAS is shown to be associated with increased incidence of MS (22). Recently, it has also been proposed that OSAS could represent a component of MS. In this study, we aimed to assess MS prevalence in patients with OSAS and to evaluate the relationship between sleep parameters and MS incidence.

Materials and Methods

Study population and design

Male and female consecutive patients between 20 and 70 years of age and without a prior diagnosis of OSAS, who arrived at the Sleep Disorders Center, Diskapi Yildirim Beyazit Training and Research Hospital Ministry of Health with complaints of snoring, witnessed apnea and excessive daytime sleepiness, were included in this study. The study complied with the Declaration of Helsinki and was approved by the local research ethics committee. All subjects provided written informed consent.

While at the Center, patients underwent polysomnographic (PSG) testing, completed a questionnaire, had physical examinations and blood sample collections.

Questionnaire and physical examinations

A standard questionnaire was administered on the day of PSG testing in order to collect information regarding medical history (including history of sleeping disorders) and family history. A physical examination was also performed. Waist circumference was measured at the narrowest part between the lowest rib margin and the iliac crest with a non-stretchable measuring tape (patients removed all clothing except underwear and were standing for the waist circumference measurements). Weight and height were also measured, and body mass index (BMI) was calculated.

Blood pressure measurements were performed between 8 and 11 a.m. in the right arm with a mercury sphygmomanometer while the patient was sitting in an upright position and following at least 10 minutes of rest. Cigarette smoking and caffeine consumption (coffee, cola etc.) were not allowed for 60 min before the readings. Measurements were performed in both arms and after 5 min, a second measurement was done in the arm with the higher reading. A third measurement was done when the difference between the first and second measurements exceeded 5 mmHg.

Polysomnography and OSAS diagnosis/classifications

Sixteen-channel PSG recordings (electroencephalography, electrooculography, electromyography of chin and leg [anterior tibialis], electrocardiography, oxygen saturation [from finger tips], respiratory effort [thoracic, abdominal] and nasal air flow, body position and tracheal microphone) were obtained for 6-8 hours with the Embla[R]-flaga instrument. PSG recordings were analyzed by a physician experienced in sleeping disorders by using Somnologica 3.2 software.

Patients with a minimal sleep efficacy of 60% were included in this study. Apnea was defined as complete cessation of airflow for at least 10 seconds, while hypopnea was defined as a 50% decrease in airflow accompanied by development of arousal from sleep or at least a 4% drop in oxygen saturation (criteria proposed by the American Association of Sleep Medicine, 1999). Oxygen desaturation time (ODT) was defined as the duration of time when the oxygen saturation of blood was below 90%. The diagnosis of OSAS was defined by the apnea-hypopnea index (AHI). AHI was calculated by dividing the total number of apnea and hypopnea events during sleep by the total number of hours of sleep. The control group in this study consisted of patients who were classified as normal since they had an AHI <5. The patient group in this study consisted of those with an AHI [greater than or equal to] 5. OSAS severity based on AHI was determined as follows: mild (5-14.9), moderate (15-29.9) and severe ([greater than or equal to] 30).

Blood sample collections

In the morning of the PSG monitoring, venous blood samples were taken for measurements of fasting blood glucose (hexokinase method using Autoanalyser AU5200), triglycerides (glycerophosphate oxidase method using Autoanalyser AU5200), and high-density lipoprotein (HDL) cholesterol (spectrophotometric method using Roche-Hitachi Modular P device).

Diagnosis of metabolic syndrome

The diagnosis of MS was based on the National Cholesterol Education Program criteria (23). An MS diagnosis was made if three or more of the following risk factors were present: waist circumference >88 cm (female) or >102 cm (male); triglycerides [greater than or equal to] 150 mg/dL; HDL cholesterol <50 mg/dL (female) or <40 mg/dL (male); blood pressure [greater than or equal to] 130/85 mmHg; and fasting blood glucose [greater than or equal to] 110 mg/dL.

Statistical analyses

Data analyses were performed with SPSS 13.0 for Windows. The continuous variables were presented as mean [+ or -] standard deviation or median (min-max), whereas categorical variables were presented as %. The presence of parametric distribution of the continuous variables was investigated by Shapiro-Wilks' test.

The Student's [dagger] or Mann-Whitney tests were used in order to determine if there were any significant differences between groups. A one-way analysis of variance (ANOVA) or the Kruskal-Wallis test were used in order to evaluate the significance of differences in continuous variables between the groups, in the presence of more than two independent groups. In the presence of significant differences, Tukey's multiple comparison where the ANOVA test had been used, and the Bonferroni correction where the Kruskal-Wallis test had used, were performed in order to identify the group(s) that caused the difference. The Mann-Whitney test was also used to perform multiple comparisons.

The significance of a linear relation between the ODT, AHI and MS components was evaluated by Spearman's correlation test. Chi-square or Fisher's exact test were used for categorical comparison. For the prediction of MS, ROC analysis was done in order to introduce the effect of ODT, and then the area under the curve (AUC), the best intersection point and the sensitivity and specificity levels in this point were calculated. The logistic regression analysis was used in order to examine the multiple effects of variables that have significant effects in the results of mono-variable analysis on the MS. The odds ratio and 95% confidence intervals were calculated. P < 0.05 was accepted as statistically significant for the results.


A total of 101 patients were included in the study, with 32 females (31.7%) and 69 males (68.3%). Twenty-one (20.8%) cases with AHI <5 were included the control group, and 80 (79.2%) cases with AHI [greater than or equal to] 5 (indicating an OSAS diagnosis) were included the patient group. The demographic features, MS components and MS prevalence of the control and patient groups are shown in Table 1. No significant differences between the patient group and control group were found for age, sex, smoking, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, hyperlipidemia, or coronary artery disease. MS prevalence, waist circumference, triglyceride levels and BMI were found to be significantly higher in the patient group than in the control group. Although systolic blood pressure has a tendency to increase proportionally with OSAS severity, there was no statistically significant difference in blood pressure between the patient and control groups (Table 1).

Table 2 presents the MS prevalence and MS components for the control and patient groups, with the patients divided into three sub-groups according to OSAS severity based on AHI levels (mild=5-14.9, moderate=15-29.9, and severe [greater than or equal to] 30). The prevalence of MS in the mild, moderate, and severe OSAS sub-groups were 51.7% (15/29), 77.8% (14/18), and 72.7% (24/33), respectively. The MS prevalence in the control group was only 33.3% (7/21), and the differences in MS prevalences between controls and each OSAS sub-group were statistically significant. No significant correlations were identified between the AHI and any components of MS; however, there was a significant positive correlation between AHI and BMI (rho=0.323, p=0.003).

In Table 3, metabolic parameters are presented for the 80 OSAS patients, divided into two sub-groups according to ODT (<5.75 min and [greater than or equal to] 5.75 min). Statistically significant differences between these two ODT sub-groups were found for waist circumference, BMI and MS prevalence. Furthermore, there was a positive correlation between ODT and waist circumference (rho=0.557, p=0.001) and between ODT and fasting blood glucose levels (rho=0.203, p=0.04).

We also found that the prevalence of MS showed a statistically significant difference (p=0.005) between the two ODT sub-groups, with an MS incidence of 74.2% (46/62) in patients with ODT [greater than or equal to] 5.75, and 38.9% (7/18) in patients with ODT <5.75.

The logistic regression analysis with multiple variables, which was done by inclusion of criteria of AHI [greater than or equal to] 5, BMI [greater than or equal to] 27 kg/[m.sup.2], age and ODT [greater than or equal to] 5.75, is presented in Table 4. It was determined that BMI, ODT and age increase the risk of MS independent of other risk factors.


In patients with OSAS, there is an increase in cardiovascular risk factors (including endothelial dysfunction, neurohumoral disorders, and systemic inflammation) as well as in hypertension, insulin resistance, impaired glucose tolerance, and dyslipidemia. Because MS also includes these same risk factors, the similarities between these two syndromes were realized, and in 1990 the co-existence of MS and OSAS was named "Syndrome Z" (24).

There are studies that show that chronic intermittent hypoxemia has a role in the development of metabolic disorders in patients with OSAS. It has been reported that chronic intermittent hypoxemia increases fasting blood glucose levels and disorders in glucose tolerance and insulin resistance via increased sympathetic activation in animal studies (25). It has also been shown that intermittent hypoxia is related to clinical cases of hypertension (26), insulin resistance (27,28), atherogenic dyslipidemia (29), neurohumoral disorders (30), pulmonary hypertension (4), endothelial dysfunction (7), and inflammation (11). In addition, effective treatment of OSAS with continuous positive airway pressure (CPAP) can lead to reduced cardiovascular mortality and morbidity by decreasing chronic intermittent hypoxemia, and thus decreasing sympathetic activity (31), reducing blood pressure and increasing insulin sensitivity. This observation supports the importance of intermittent hypoxemia in the pathogenesis of MS in patients with OSAS.

There are several studies that have evaluated the prevalance of MS and the relative risks by using AHI in patients with OSAS. Coughlin et al found the prevalence of MS to be 83% in patients with OSAS and AHI greater than 15. In a study by Gruber et al, there was a 6-fold increase in the risk of MS (32). Lam et al determined the prevalence of MS to be 37% in patients with an AHI greater than 5, and reported that OSAS causes a 5-fold increase in the risk of MS (33). Lastly, Sasanabe et al also determined an important increase in the prevalence of MS in patients with an AHI greater than 15 (34). Consistent with these findings, data from this current study show that OSAS increases the risk of MS by 9 times.

Also similar to other previous studies, we found increases in BMI, waist circumference, triglyceride levels and MS prevalences in patients with OSAS. Although there was an increase in systolic blood pressure levels in the patient group compared to the control group, this finding was not statistically significant. However, when patients in this study were divided into sub-groups according to their ODT during sleep, there was a significant increase in MS prevalence, waist circumference and BMI in the patients with ODT [greater than or equal to] 5.75. In the multiple logistic regression analysis, in which the criteria of AHI [greater than or equal to] 5, BMI [greater than or equal to] 27 kg/[m.sup.2], age and ODT [greater than or equal to] 5.75 were included, it was determined that age, ODT and BMI increased the risk of MS independent of other risk factors; AHI did not cause a significant increase in the risk of MS.

The observation that ODT increases the risk of MS independent of other risk factors is important. Specifically, in patients with mild OSAS (based on AHI), the ODT may be prolonged and reach levels comparable to those in patients with moderate or severe OSAS. In this situation, the risk of MS and the risk of coexisting cardiovascular disease in the mild OSAS patients may actually be greater than anticipated. It has been suggested that ODT is a more reliable parameter than AHI in the determining MS and coexisting cardiovascular disease risks. In one recently published study, patients with OSAS, who had no additional cardiovascular diseases or risk factors, were evaluated for heart type fatty acid binding protein (h-fabp) levels. H-fabp, which is a very sensitive and specific marker of myocardial damage, was found to be higher in the patient group than in the control group. The high h-fabp levels in OSAS patients were related to the ODT spent under 80% and 90% during sleep. There was no relationship between h-fabp levels and AHI. These data support the theory that ODT is more important than AHI in the development of cardiovascular diseases in patients with OSAS (35). In conclusion, in this study we showed that the increased risk of MS in patients with OSAS is related to the ODT, and is independent of AHI and other risk factors. The time of hypoxia increases the risk of MS and the risk of coexisting cardiovascular disease independent of the current disease classification which is done by AHI. Therefore, it is a rational approach to consider ODT, in addition to AHI, in the cardiovascular risk assessment of patients with OSAS.


(1.) Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003; 41: 1429-37.

(2.) Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-5.

(3.) Peppard PE, Young T, Patla M, Skatrud J. Prospective study of the association between sleep-disorder breathing and hypertension. N Engl J Med 2000; 342: 1378-4.

(4.) Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disorder breathing, sleep apnea, and hypertension in large community-based study. Sleep Heart Healty Study. JAMA. 2000; 283: 1829-36.

(5.) Sanner BM, Doberaurer C, Konermenn M, Sturm A, Zidek W. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 1997; 157: 2483-7.

(6.) Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000; 55: 934-9.

(7.) Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002; 69: 229-34.

(8.) Wang Y, Yang H, Dong M. Study on the levels of C-reactive protein and fibrinolytic activity in patients with obstructive sleep apnea syndrome. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004; 18: 147-8.

(9.) Kato M, Roberts-Thomson P, Philips BG, Haynes WG, Winnicki M, Accurso V, Somers VK. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102: 2607-10.

(10.) Duchna HW, Orth M, Schultze-Werninghaus G, Guilleminault C, Stoohs RA. Long-term effects of nasal continuous positive airway pressure on vasodilatory endothelial function in obstructive sleep apnea syndrome. Sleep Breath 2005; 9: 97-103.

(11.) Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4.

(12.) Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-34.

(13.) Schafer H, Koahler U, Ploch T, Peter JH. Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 1997; 111: 387-93.

(14.) Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000; 16: 128-33.

(15.) Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-6.

(16.) Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002; 165: 677-82.

(17.) Ip MS, Lam KS, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-6.

(18.) Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-20.

(19.) Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-6.

(20.) Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548-53.

(21.) Onat A, Sansoy V. Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk. Turk Kardiyol Dern Ars 2002; 30: 8-15.

(22.) Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-41.

(23.) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

(24.) Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998; 53: S25-8.

(25.) Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-1904.

(26.) Fletcher EC. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol 2000; 119: 189-97.

(27.) Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR, O'Donnell CP. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552: 253-64.

(28.) Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, Polotsky VY, O'Donnell CP. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-7.

(29.) Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-63.

(30.) Pepin JL, Levy P (2002) Pathophysiology of cardiovascular risk in sleep apnea syndrome (SAS). Rev Neurol (Paris) 158: 785-97.

(31.) Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100: 2332-5.

(32.) Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.

(33.) Lam JC, Lam B, Lam CL, Fong D, Wang JK, Tse HF, Lam KS, Ip MS. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese adults in Hong Kong. Respir Med 2006; 100: 980-7.

(34.) Sasanabe R, Banno K, Otake K, Hasegawa R, Usui K, Morita M, Shiomi T. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens Res 2006; 29: 315-22.

(35.) Oktay B, Akbal E, Firat H, Ardic S, Akdemir R, Kizilgun M. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath 2008; 12: 223-8.

Erdem Akbal, Burcu Oktay *, Hikmet Firat *, Mustafa Ozbek **, Sadik Ardic *, Murat Kizilgun ***

Diskapi Yildirim Beyazit Education and Research Hospital, Internal Medicine, Ankara, Turkey

* Diskapi Yildirim Beyazit Education and Research Hospital, Chest Medicine, Ankara, Turkey

** Diskapi Yildirim Beyazit Education and Research Hospital, Endocrinology and Metabolism, Ankara, Turkey

*** Diskapi Ankara Pediatrics Training and Research Hospital, Biochemistry, Ankara, Turkey

Address for Correspondence: Erdem Akbal, MD, Diskapi Yildirim Beyazit Education and Research Hospital, Internal Medicine, Ankara, Turkey E-mail: Received: 26.07.2008 Accepted: 24.10.2008
Table 1. Demographic features, metabolic syndrome components
and prevalences

Variables Controls Patients
 (N=21) (N=80)

Age (years) 49.3 [+ or -] 11 50.9 [+ or -] 9
Sex (male) 66% 68%
Smoking (packet/years) 12 (0-90) 6 (0-90)
BMI (kg/[m.sup.2]) 28.8 [+ or -] 4.3 32.6 [+ or -] 6.0
Diabetes mellitus (%) 0 7.5%
Hypertension (%) 19% 23.8%
Coronary artery
 disease (%) 0 4.8%
Chronic obstructive lung
 disease (%) 4.8% 6.3%
Hypertriglyceridemia (%) 0 0
Systolic blood pressure
 (mmHg) 120.4 [+ or -] 19.2 125.0 [+ or -] 20.7
Diastolic blood pressure
 (mmHg) 83.0 [+ or -] 12.9 83.9 [+ or -] 13.2
Fasting Blood Glucose
 (mg/dL) 107.7 [+ or -] 38.2 116.0 [+ or -] 43.8
Waist circumferences (cm) 96.2 [+ or -] 14.6 108.2 [+ or -] 11.5
Triglyceride (mg/dL) 143.7 [+ or -] 55.5 173.0 [+ or -] 71.1
HDL-C (mg/dL) 43.1 [+ or -] 9.0 43.3 [+ or -] 8.9
Prevalance of MS (%) 3.3% 66.3%

Variables p value

Age (years) > 0.05 (a)
Sex (male) > 0.05 (b)
Smoking (packet/years) > 0.05 (c)
BMI (kg/[m.sup.2]) 0.008 (c)
Diabetes mellitus (%) 0.198 (d)
Hypertension (%) 0.490 (d)
Coronary artery
 disease (%) 0.060 (d)
Chronic obstructive lung
 disease (%) 0.798 (d)
Hypertriglyceridemia (%) 1
Systolic blood pressure
 (mmHg) 0.363 (c)
Diastolic blood pressure
 (mmHg) 0.796 (c)
Fasting Blood Glucose
 (mg/dL) 0.428 (c)
Waist circumferences (cm) < 0.001 (a)
Triglyceride (mg/dL) 0.040 (c)
HDL-C (mg/dL) 0.930 (c)
Prevalance of MS (%) 0.006 (b)

BMI: body mass index; HDL-C: high-density lipoprotein cholesterol;
MS: metabolic syndrome (a) Student's (b) Pearson Chi-square test;
(c) Mann-Whitney U test; (d) Fisher's Exact test t test;

Table 2. Sleep parameters and components of meta
for controls and patients (divided into sub-groups
based on OSAS severity)

Variables Controls Mild OSAS
 (N=21) (N=29)

AHI (events/h)(a) 2.3 [+ or -] 1.2 9.7 [+ or -] 2.7 *
ODT (min) (a) 3.6 [+ or -] 5.9 53.5 [+ or -] 44.1 *
Systolic blood
 pressure (mmHg) (a) 120.4 [+ or -] 19.2 122.2 [+ or -] 20.8
Diastolic blood
 pressure (mmHg) (a) 83.0 [+ or -] 12.9 81.3 [+ or -] 11.2
Fasting plasma glucose
 (mg/dL) (a) 107.7 [+ or -] 38.2 112.4 [+ or -] 41.9
Waist circumferences
 (cm) (b) 96.2 [+ or -] 14.6 105.4 [+ or -] 11.5 **
 (mg/dL) (b) 143.7 [+ or -] 55.5 164 [+ or -] 62.0
HDL-C (mg/dL) (a) 43.1 [+ or -] 9.0 42.8 [+ or -] 8.8
BMI (kg/[m.sup.2]) (a) 28.8 [+ or -] 4.3 30.5 [+ or -] 4.6
Prevalance of MS 33.3% 51.7%
 (%) (c)
 (7/21) (15/29)

Variables Moderate OSAS Severe OSAS
 (N=18) (N=33)

AHI (events/h)(a) 21.3 [+ or -] 4.9 * 63.2 [+ or -] 19.5 *
ODT (min) (a) 72.9 [+ or -] 68.2 * 207.0 [+ or -] 131.5 *
Systolic blood
 pressure (mmHg) (a) 124.4 [+ or -] 14.6 127.8 [+ or -] 23.4
Diastolic blood
 pressure (mmHg) (a) 83.0 [+ or -] 9.5 86.6 [+ or -] 16.2
Fasting plasma glucose
 (mg/dL) (a) 119.6 [+ or -] 24.5 119.6 [+ or -] 53.4
Waist circumferences
 (cm) (b) 109.1 [+ or -] 10.6 ** 110.1 [+ or -] 11.9 **
 (mg/dL) (b) 167.5 [+ or -] 64.5 183.3 [+ or -] 78.7
HDL-C (mg/dL) (a) 43.0 [+ or -] 7.9 43.8 [+ or -] 9.8
BMI (kg/[m.sup.2]) (a) 31.6 [+ or -] 4.4 35.0 [+ or -] 7.1 ***
Prevalance of MS 77.8% 72.7%
 (%) (c)
 (14/18) (24/33)

OSAS: obstructive sleep apnea syndrome; AHI: apnea-hypopnea index;
ODT: oxygen desaturation time; HDL-C: high-densitiy lipoprotein
cholesterol; BMI: body mass index; MS: metabolic syndrome

(a) Kruskal-Wallis test; (b) One-way ANOVA;
(c) Pearson Chi-square test

* p <0.01 (mild, moderate, severe OSAS vs. control);
** p = 0.01 (mild, moderate, severe OSAS vs. control);
*** p <0.001(severe OSAS vs. control)

Table 3. Sleep parameters and components of metabolic syndrome
for controls and patients (divided into sub-groups based on
OSAS severity)

Variables ODT < 5.75 minutes ODT [greater than
 (N=18) or equal to] 5.75

Systolic blood pressure
 (mm Hg) 118 [+ or -] 15.2 126 [+ or -] 21.8
Diastolic blood pressure
 (mm Hg) 81.1 [+ or -] 10.7 84.7 [+ or -] 13.9
Fasting blood glucose
 (mg/dL) 104.7 [+ or -] 26.1 119.3 [+ or -] 47.4
Waist circumferences (cm) 101.2 [+ or -] 10.7 110.2 [+ or -] 11.0
Triglyceride (mg/dL) 176.0 [+ or -] 65.1 173.2 [+ or -] 73.2
HDL-C (mg/dL) 44.3 [+ or -] 11.1 43.0 [+ or -] 8.3
BMI (kg/[m.sup.2]) 29.0 [+ or -] 4.2 33.7 [+ or -] 6.11
Prevalance of MS (%) 38.9% 74.2%
 (7/18) (46/62)

Variables p values

Systolic blood pressure
 (mm Hg) 0.158 (a)
Diastolic blood pressure
 (mm Hg) 0.309 (a)
Fasting blood glucose
 (mg/dL) 0.217 (a)
Waist circumferences (cm) 0.030 (b)
Triglyceride (mg/dL) 0.880 (a)
HDL-C (mg/dL) 0.596 (a)
BMI (kg/[m.sup.2]) 0.030 (a)
Prevalance of MS (%) 0.005 (c)

ODT: oxygen desaturation time; HDL-C: high-densitiy lipoprotein
cholesterol; BMI: body mass index; MS: metabolic syndrome

(a) Mann-Whitney U test; (b) Student's t test;
(c) Pearson Chi-square test

Table 4. Logistic regression analysis

Variables Exp(b) 95% CI for p value

ODT [greater than or equal to] 5.75
 minutes 9.5 1.25-18.21 0.022
Age 2.14 1.23-3.75 < 0.001
BMI [greater than or equal to] 27
 kg/[m.sup.2] 7.743 1.97-30.41 0.003
AHI [greater than or equal to] 5
 events/h 1.00 0.98-1.02 0.405

ODT: oxygen desaturation time; BMI: body mass index;
AHI: apnea-hypopnea index; exp(b): intersection point;
CI: confidence interval
COPYRIGHT 2008 Galenos Yayincilik
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article/Orijinal Makale
Author:Akbal, Erdem; Oktay, Burcu; Firat, Hikmet; Ozbek, Mustafa; Ardic, Sadik; Kizilgun, Murat
Publication:Turkish Journal of Endocrinology and Metabolism
Article Type:Report
Geographic Code:7TURK
Date:Sep 1, 2008
Next Article:Evaluation of life quality functions in patients with type 2 diabetes mellitus/ Tip 2 diabetes mellitus'lu hastalarin yasam kalitesi fonksiyonlarinin...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters